Histogen jumps on positive results from early-stage COVID-19 drug trial

Histogen

22/06/2021 14:16

** Shares of clinical-stage therapeutics company  HSTO.O  up
10% premarket at $1.04 
    ** Co says early-stage study demonstrated that its
experimental drug, emricasan, was safe and well-tolerated in
mild symptomatic COVID-19 patients as compared with placebo,
with no reports of serious adverse events  urn:newsml:reuters.com:*:nGNX3TztVZ
    ** Study conducted along with partner Amerimmune LLC
    ** Patients who completed treatment with emricasan had a
complete resolution of the symptoms most commonly associated
with mild COVID-19, such as cough, headache and fatigue - co
    ** Up to Monday's close, stock has gained nearly 25% so far
this year
    

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))